Artrya Enters Agreement With US Foundation Partner for Clinical Use of Platform; Shares Rise 9%

MT Newswires Live

Dec 08, 2025

Artrya (ASX:AYA) entered a three-year commercial agreement with Northeast Georgia Health System (NGHS) for the clinical use of Salix, the company's cloud platform for the assessment and management of coronary artery disease, according to a Monday filing with the Australian bourse.

Under the deal, Salix will be used for patients with suspected or confirmed coronary artery disease undergoing CT angiography within the Georgia Heart Institute, the filing said.

Salix will be licensed as a SaaS platform with a fixed monthly subscription fee, the filing added.

Assessments performed using Salix's plaque module will generate fee-per-scan revenue, the company said.

The company is preparing the US Food and Drug Administration submission for Salix's coronary flow module.

Shares of the company rose 9% in recent Monday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2589043908"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589043908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589043908?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 08:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589043908","market":"fut","top_or_hot":-1,"title":"Artrya Enters Agreement With US Foundation Partner for Clinical Use of Platform; Shares Rise 9%","media":"MT Newswires Live","content":"<html><body><p> Artrya (ASX:AYA) entered a three-year commercial agreement with Northeast Georgia Health System (NGHS) for the clinical use of Salix, the company's cloud platform for the assessment and management of coronary artery disease, according to a Monday filing with the Australian bourse.</p><p>Under the deal, Salix will be used for patients with suspected or confirmed coronary artery disease undergoing CT angiography within the Georgia Heart Institute, the filing said.</p><p>Salix will be licensed as a SaaS platform with a fixed monthly subscription fee, the filing added.</p><p>Assessments performed using Salix's plaque module will generate fee-per-scan revenue, the company said.</p><p>The company is preparing the US Food and Drug Administration submission for Salix's coronary flow module.</p><p>Shares of the company rose 9% in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artrya Enters Agreement With US Foundation Partner for Clinical Use of Platform; Shares Rise 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtrya Enters Agreement With US Foundation Partner for Clinical Use of Platform; Shares Rise 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-08 08:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Artrya (ASX:AYA) entered a three-year commercial agreement with Northeast Georgia Health System (NGHS) for the clinical use of Salix, the company's cloud platform for the assessment and management of coronary artery disease, according to a Monday filing with the Australian bourse.</p><p>Under the deal, Salix will be used for patients with suspected or confirmed coronary artery disease undergoing CT angiography within the Georgia Heart Institute, the filing said.</p><p>Salix will be licensed as a SaaS platform with a fixed monthly subscription fee, the filing added.</p><p>Assessments performed using Salix's plaque module will generate fee-per-scan revenue, the company said.</p><p>The company is preparing the US Food and Drug Administration submission for Salix's coronary flow module.</p><p>Shares of the company rose 9% in recent Monday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AYA.AU","symbol_name":"ARTRYA LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2589043908","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589043908","pubTimestamp":1765153156,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Artrya  entered a three-year commercial agreement with Northeast Georgia Health System  for the clinical use of Salix, the company's cloud platform for the assessment and management of coronary artery disease, according to a Monday filing with the Australian bourse.Under the deal, Salix will be used for patients with suspected or confirmed coronary artery disease undergoing CT angiography within the Georgia Heart Institute, the filing said.Salix will be licensed as a SaaS platform with a fixed monthly subscription fee, the filing added.Assessments performed using Salix's plaque module will generate fee-per-scan revenue, the company said.The company is preparing the US Food and Drug Administration submission for Salix's coronary flow module.Shares of the company rose 9% in recent Monday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AYA.AU":"ARTRYA LTD","BK7094":"医疗保健技术"},"translate_title":"Artrya与美国基金会合作伙伴就平台的临床使用达成协议；股价上涨9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AYA.AU":1},"content_text":"Artrya (ASX:AYA) entered a three-year commercial agreement with Northeast Georgia Health System (NGHS) for the clinical use of Salix, the company's cloud platform for the assessment and management of coronary artery disease, according to a Monday filing with the Australian bourse.Under the deal, Salix will be used for patients with suspected or confirmed coronary artery disease undergoing CT angiography within the Georgia Heart Institute, the filing said.Salix will be licensed as a SaaS platform with a fixed monthly subscription fee, the filing added.Assessments performed using Salix's plaque module will generate fee-per-scan revenue, the company said.The company is preparing the US Food and Drug Administration submission for Salix's coronary flow module.Shares of the company rose 9% in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}